vs
Side-by-side financial comparison of GRACO INC (GGG) and Bio-Techne (TECH). Click either name above to swap in a different company.
GRACO INC is the larger business by last-quarter revenue ($593.2M vs $311.4M, roughly 1.9× Bio-Techne). GRACO INC runs the higher net margin — 22.3% vs 16.4%, a 5.9% gap on every dollar of revenue. On growth, GRACO INC posted the faster year-over-year revenue change (8.1% vs -1.5%). Over the past eight quarters, GRACO INC's revenue compounded faster (9.8% CAGR vs 1.3%).
Graco Inc. is an American industrial company that specializes in the development and manufacturing of fluid-handling systems and products. The company is headquartered in Minneapolis, Minnesota, and markets its products to customers worldwide.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
GGG vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $593.2M | $311.4M |
| Net Profit | $132.5M | $51.0M |
| Gross Margin | 51.7% | 66.9% |
| Operating Margin | 26.7% | 24.2% |
| Net Margin | 22.3% | 16.4% |
| Revenue YoY | 8.1% | -1.5% |
| Net Profit YoY | 21.9% | 126.0% |
| EPS (diluted) | $0.78 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $593.2M | $295.9M | ||
| Q3 25 | $543.4M | — | ||
| Q2 25 | $571.8M | $317.0M | ||
| Q1 25 | $528.3M | $316.2M | ||
| Q4 24 | $548.7M | $297.0M | ||
| Q3 24 | $519.2M | $289.5M | ||
| Q2 24 | $553.2M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $132.5M | $38.0M | ||
| Q3 25 | $137.6M | — | ||
| Q2 25 | $127.6M | $-17.7M | ||
| Q1 25 | $124.1M | $22.6M | ||
| Q4 24 | $108.7M | $34.9M | ||
| Q3 24 | $122.2M | $33.6M | ||
| Q2 24 | $133.0M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 51.7% | 64.6% | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 52.4% | 62.7% | ||
| Q1 25 | 52.6% | 67.9% | ||
| Q4 24 | 50.9% | 65.3% | ||
| Q3 24 | 53.2% | 63.2% | ||
| Q2 24 | 54.4% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 26.7% | 18.4% | ||
| Q3 25 | 30.3% | — | ||
| Q2 25 | 27.5% | -7.5% | ||
| Q1 25 | 27.3% | 12.2% | ||
| Q4 24 | 23.7% | 16.0% | ||
| Q3 24 | 28.1% | 13.8% | ||
| Q2 24 | 29.2% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | 22.3% | 12.8% | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 22.3% | -5.6% | ||
| Q1 25 | 23.5% | 7.1% | ||
| Q4 24 | 19.8% | 11.7% | ||
| Q3 24 | 23.5% | 11.6% | ||
| Q2 24 | 24.0% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.78 | $0.24 | ||
| Q3 25 | $0.82 | — | ||
| Q2 25 | $0.76 | $-0.11 | ||
| Q1 25 | $0.72 | $0.14 | ||
| Q4 24 | $0.63 | $0.22 | ||
| Q3 24 | $0.71 | $0.21 | ||
| Q2 24 | $0.77 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $624.1M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $2.1B |
| Total Assets | $3.3B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $624.1M | $172.9M | ||
| Q3 25 | $618.7M | — | ||
| Q2 25 | $534.9M | $162.2M | ||
| Q1 25 | $536.1M | $140.7M | ||
| Q4 24 | $675.3M | $177.5M | ||
| Q3 24 | $764.5M | $187.5M | ||
| Q2 24 | $666.0M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.7B | $2.0B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.5B | $2.0B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.5B | $2.1B | ||
| Q2 24 | $2.4B | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $3.3B | $2.5B | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.0B | $2.6B | ||
| Q1 25 | $3.0B | $2.6B | ||
| Q4 24 | $3.1B | $2.7B | ||
| Q3 24 | $3.0B | $2.7B | ||
| Q2 24 | $2.9B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $196.3M | — |
| Free Cash FlowOCF − Capex | $184.3M | — |
| FCF MarginFCF / Revenue | 31.1% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 1.48× | — |
| TTM Free Cash FlowTrailing 4 quarters | $637.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $196.3M | — | ||
| Q3 25 | $179.2M | — | ||
| Q2 25 | $182.7M | $98.2M | ||
| Q1 25 | $125.4M | $41.1M | ||
| Q4 24 | $185.2M | $84.3M | ||
| Q3 24 | $178.6M | $63.9M | ||
| Q2 24 | $139.0M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $184.3M | — | ||
| Q3 25 | $175.7M | — | ||
| Q2 25 | $163.1M | $93.3M | ||
| Q1 25 | $114.8M | $31.0M | ||
| Q4 24 | $171.3M | $77.5M | ||
| Q3 24 | $159.2M | $54.7M | ||
| Q2 24 | $102.7M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | 31.1% | — | ||
| Q3 25 | 32.3% | — | ||
| Q2 25 | 28.5% | 29.4% | ||
| Q1 25 | 21.7% | 9.8% | ||
| Q4 24 | 31.2% | 26.1% | ||
| Q3 24 | 30.7% | 18.9% | ||
| Q2 24 | 18.6% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 3.4% | 1.5% | ||
| Q1 25 | 2.0% | 3.2% | ||
| Q4 24 | 2.5% | 2.3% | ||
| Q3 24 | 3.7% | 3.2% | ||
| Q2 24 | 6.6% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | — | ||
| Q3 25 | 1.30× | — | ||
| Q2 25 | 1.43× | — | ||
| Q1 25 | 1.01× | 1.82× | ||
| Q4 24 | 1.70× | 2.42× | ||
| Q3 24 | 1.46× | 1.90× | ||
| Q2 24 | 1.05× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GGG
| Industrial | $284.3M | 48% |
| Contractor | $265.5M | 45% |
| Other | $43.4M | 7% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
